BioElectronics Corporation Enters Into a Distribution Agreement For RecoveryRx in Spain With PRIM Group
BioElectronics Corporation (BIEL) announced a distribution agreement with Spain's PRIM Group for its RecoveryRx device. This device is designed to provide drug-free pain relief post-surgery and offers 720 hours of therapy. The partnership aims to strengthen BioElectronics' market presence in Spain, with PRIM handling sales, marketing, and distribution. RecoveryRx is both FDA cleared and CE marked, affirming its compliance with regulatory standards. This move aligns with the company's strategy to expand its distribution network across Europe.
- Established distribution agreement with PRIM Group in Spain, expanding market presence.
- RecoveryRx device designed for drug-free post-surgical pain relief, enhancing product offerings.
- RecoveryRx is FDA cleared and CE marked, validating its regulatory compliance.
- None.
FREDERICK, MD, April 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announced that the Company has entered into a distribution agreement with Madrid / Spain based PRIM Group (www.prim.es) for the distribution of its RecoveryRx device throughout Spain.
"PRIM Group in Spain serves as a perfect call point fit to provide a successful distribution of RecoveryRx in an important market in Europe,” said Kelly Whelan, President of BioElectronics.
“Our goal is to continue expanding our network of qualified distributors with knowledgeable sales and support personnel, and in close proximity to our customers,” added Erin Sanders, Manager of International Sales for BioElectronics Corporation.
PRIM Group is expected to provide sales, marketing, and distribution services throughout Spain for RecoveryRx. The RecoveryRx medical device is designed to provide drug-free relief of post-surgical pain. RecoveryRx is a single use device designed to provide 720 hours of therapy. RecoveryRx is both US FDA cleared, and CE marked.
About PRIM Group: PRIM is a Spanish public company that has been listed on the Stock Exchange since 1985 and adds value to the healthcare system. PRIM designs, manufactures, commercializes, installs and keeps products and equipment providing advanced solutions. PRIM provides comprehensive continuous service via its headquarter offices, two plants, seven regional offices, four warehouses and six orthopedic clinics. It develops its main activity in Hospitals, Clinics, Healthcare Centers, Health Insurances, Orthopedics, Individuals, Chiropody Centers, Chemist's, and Medical Societies.
About BioElectronics: BioElectronics Corporation is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx® Devices for post-operative pain and wound care. For more information, visit www.bielcorp.com
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
949.697.1323
FAQ
What is the significance of the distribution agreement between BioElectronics and PRIM Group?
What is the RecoveryRx device used for?
Is the RecoveryRx device approved by regulatory bodies?
What are the future goals of BioElectronics following this announcement?
